TorpedoDx is reducing global cancer mortality through the early detection of cancer, guiding precision therapy selection, and monitoring patients to manage cancer as a chronic disease. We provide information-rich answers to complex cancer questions from a simple blood draw. TorpedoDx employs a patented approach to analyze circulating tumor cells, known as CTCs. The approach starts with a simple microfluidic device that removes red blood cells, platelets, and normal white blood cells to produce a highly-enriched population of residual cells containing all CTCs available in the blood sample. Digital PCR and RNA sequencing are coupled with machine learning algorithms to detect and characterize the tumor cells.
- Darren Link, PhD President & CEO
- Brian Hutchison, PhD Vice President, Development & Operations